TP53 and malignant glioma: Preclinical studies of ONYX-015 in human malignant glioma xenografts derived from primary tumors demonstrated a high anti-tumor activity and widespread intratumoral replication in p53 wild-type tumors as well as p53-mutant tumors [117].